The Ebola vaccine projects – EBOVAC1, EBOVAC2, EBODAC and EBOMAN – are among the eight projects funded under the IMI Ebola+ programme that was launched in response to the Ebola Virus Disease outbreak.

Phase 1 trials are being carried out in the UK, Kenya, Tanzania and Uganda. These Phase 1 safety trials are gathering preliminary information on the safety and tolerability of the vaccine regimen. The immune response generated by the regimen will also be evaluated longer term.

The first published clinical data from the Phase 1 site in Oxford, UK, suggests that the regimen was well-tolerated by healthy volunteers and immunogenic. Among the findings, 100 percent of participants in the study achieved an initial antibody response to Ebola, and this response was sustained 8 months following immunization.

The Phase 1 studies in Africa are coordinated by Dr Deborah Watson-Jones, Clinical Epidemiologist, here, at the London School of Hygiene & Tropical Medicine.

Please visit the EBOVAC website to find out more: www.ebovac.org